July 8, 2020 / 9:54 PM / a month ago

BRIEF-Anaptysbio Announces Orphan Drug Designation Of Imsidolimab For Treatment Of Generalized Pustular Psoriasis

July 8 (Reuters) - AnaptysBio Inc:

* ANAPTYSBIO ANNOUNCES ORPHAN DRUG DESIGNATION OF IMSIDOLIMAB FOR TREATMENT OF GENERALIZED PUSTULAR PSORIASIS

* ANAPTYSBIO - ADDITIONAL DATA AND REGULATORY STRATEGY UPDATE FROM GENERALIZED PUSTULAR PSORIASIS PHASE 2 GALLOP TRIAL ANTICIPATED DURING H2 2020

* ANAPTYSBIO INC - PALMOPLANTAR PUSTULOSIS (PPP) PHASE 2 POPLAR TRIAL TOP-LINE DATA ANTICIPATED IN H2 2020

* ANAPTYSBIO INC - PLANS TO EXPAND CLINICAL DEVELOPMENT OF IMSIDOLIMAB TO ADDITIONAL INDICATIONS DURING H2 2020 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below